TABLE 1.
C. difficile strains and relevant phenotypes
| Strain | Source | Description | Toxin phenotype | MIC (μg/ml) fora: |
|||
|---|---|---|---|---|---|---|---|
| LFF571 | FDX | VAN | MET | ||||
| NB95009 | ATCC 700057 | VPI 11186b | A− B− | 0.5 | 0.03 | 0.5 | 0.25 |
| NB95013 | ATCC 43255 | VPI 10463 | A+ B+ | 0.25 | 0.06 | 0.5 | 0.25 |
| NB95016 | Clinical isolatec | MOH003, ribotype AE; NAP 1 | A+ B+ CDT+ | 0.5 | 0.125 | 0.5 | 2 |
| NB95029 | Clinical isolatec | MOH118, ribotype AA | A− B+ | 0.5 | 0.125 | 0.5 | 2 |
| NB95031 | Clinical isolatec | MOH082, ribotype AA | A+ B+ | 0.5 | 0.125 | 0.5 | 2 |
a
FDX, fidaxomicin; VAN, vancomycin; MET, metronidazole.
b
CLSI MIC quality control strain.
c
Kindly provided by D. Low (Mt. Sinai Hospital, Toronto, Canada).